Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

Written by Andreas Villaester on 13th April 2022. Posted in Client News.

• Previous
• Next